Virtual Library
Start Your Search
I. Park
Author of
-
+
P1.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 206)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.01-042 - Maintenance Therapy with Pemetrexed after Induction Therapy with Pemetrexed plus Cisplatin for Advanced Pulmonary Adenocarcinoma (ID 670)
09:30 - 09:30 | Author(s): I. Park
- Abstract
Background:
Recently, continuation maintenance with Pemetrexed after induction therapy with pemetrexed plus cisplatin for advanced pulmonary adenocarcinoma has been approved in Korea. Therefore we retrospectively evaluated the activity and feasibility of continuation maintenance with Pemetrexed in Korean patients.
Methods:
Stage IIIB/V patients with pulmonary adenocarcinoma were evaluated from 2006 to 2015 April. We analyzed 12 cases with maintenance therapy with Pemetrexed. All patients received an induction phase which consisted of 4-6 cycles of induction pemetrexed (500 mg/m[2]) plus cisplatin (75 mg/m[2]) on day 1 of a 21-day cycle and maintenance therapy with pemetrexed (500 mg/m[2]) every 21 days) plus best supportive care until disease progression.
Results:
Mean age was 61 years; 9 were men. Median number of total pemetrexed cycles was 18 (8-42). The mean overall survival time and the mean progression free survival were 46±12.3 months and 21.1±5.8 months, respectively. The median overall survival time and the median progression free survival were 29±20.8 months and 12±7.1 months, respectively. Discontinuations due to drug-related adverse events occurred in one (8%) patients.
Conclusion:
Continuation maintenance with pemetrexed is an effective and well tolerated treatment option for patients with advanced pulmonary adenocarcinoma with good performance status who have not progressed after induction therapy with pemetrexed plus cisplatin in Korea.
